Amyloid Heart Disease Diagnosis: An In-Depth Guide for Automotive Repair Experts

Introduction to Amyloid Heart Disease

Amyloid heart disease, also known as cardiac amyloidosis, is a significant health condition characterized by the buildup of abnormal proteins called amyloid fibrils in the heart tissue. This accumulation leads to restrictive cardiomyopathy, a condition where the heart muscle stiffens, hindering its ability to relax and fill with blood between beats. Often underdiagnosed, amyloid heart disease requires a high level of clinical suspicion and relies heavily on advanced cardiovascular imaging techniques for accurate diagnosis. This article provides a comprehensive review of the pathophysiology, diagnostic approaches, and management strategies for different types of amyloid heart disease, emphasizing the crucial role of a multidisciplinary team in patient care.

Understanding the Etiology of Amyloid Heart Disease

Amyloid heart disease arises from the extracellular deposition of amyloid, a toxic substance composed of misfolded proteins and matrix components such as proteoglycans and collagen. The primary sources of these misfolded proteins are amyloid light chain (AL) proteins and amyloid transthyretin (ATTR).

Microscopically, amyloid fibrils are non-branching structures, approximately 7-10 nm in diameter. Their accumulation in the heart’s extracellular space leads to myocardial stiffening and impaired cardiac function, initially affecting diastolic function and later systolic function.

Several etiological types of cardiac amyloidosis are recognized:

1. Amyloid Light Chain Amyloidosis (AL): Also known as primary amyloidosis, AL amyloidosis is caused by the deposition of AL fibrils produced by abnormal plasma cells, often associated with plasma cell dyscrasias like multiple myeloma.
2. Amyloid Transthyretin Amyloidosis (ATTR): This type involves the deposition of transthyretin protein and is further divided into two subtypes:
   • Wild-type ATTR amyloidosis (ATTRwt): Formerly known as senile systemic amyloidosis, ATTRwt is age-related and involves the deposition of normal TTR protein. It is the most common form of cardiac amyloidosis.
   • Variant ATTR amyloidosis (ATTRv): Also known as familial amyloidosis, ATTRv is caused by mutations in the TTR gene, leading to the production of abnormal TTR protein.
3. Isolated Atrial Amyloidosis: This less common form results from the deposition of amyloid derived from atrial natriuretic peptide specifically within the atria.
4. AA Amyloidosis: Secondary amyloidosis, or AA amyloidosis, is triggered by chronic inflammatory conditions, leading to the deposition of serum amyloid A protein.

Epidemiological Insights into Amyloid Heart Disease

Cardiac amyloidosis is considered a rare disease overall, but its prevalence varies significantly depending on the specific type. Approximately 10% of patients with multiple myeloma develop AL amyloidosis, and cardiac involvement is seen in 50-70% of these cases. The annual incidence of AL amyloidosis is estimated at 1 per 100,000 individuals.

Familial ATTR amyloidosis prevalence is less defined due to the numerous TTR gene mutations involved. However, studies indicate the presence of certain mutations, such as V122I, in specific populations, with a prevalence of 0.0173 in an African American cohort study.

Wild-type ATTR amyloidosis is the most prevalent cardiac amyloidosis form, especially in older adults. Prevalence estimates exceed 10% in individuals over 60 years old, frequently overlapping with heart failure with preserved ejection fraction (HFpEF) diagnoses. Furthermore, ATTRwt amyloidosis may be present in at least 10% of aortic stenosis patients and 10-15% of individuals over 65 with HFpEF.

Improved diagnostic capabilities and increased awareness have led to higher reported prevalence rates of cardiac amyloidosis. Over a 12-year period, prevalence rates have risen from 8 to 17 per 100,000 person-years, highlighting the growing recognition of this condition.

Pathophysiology: How Amyloid Deposits Affect the Heart

Amyloid deposition disrupts normal heart function through several mechanisms. Interstitial infiltration directly increases ventricular wall thickness and stiffness, resulting in diastolic dysfunction. In AL amyloidosis, amyloid can deposit in small blood vessels of the heart (arterioles), potentially causing angina or, in rare instances, myocardial infarction. Atrial amyloid infiltration can create a structural basis for atrial fibrillation and increase the risk of atrial thrombosis and thromboembolism, even without atrial fibrillation. Additionally, in AL amyloidosis, light chains can directly damage heart muscle cells through reactive oxygen species.

In AL amyloidosis, abnormal light chains produced by plasma cells form amyloid fibrils. Transthyretin amyloidosis arises from the misfolding and deposition of transthyretin protein, either due to aging in ATTRwt or genetic mutations in ATTRv. Isolated atrial amyloidosis is specifically linked to amyloid formation from atrial natriuretic peptide.

History and Physical Examination in Amyloid Heart Disease Diagnosis

Patients with amyloid heart disease may present with symptoms primarily related to the heart, or cardiac involvement may be discovered during evaluations for systemic amyloidosis.

Primary cardiac symptoms include:

• Dyspnea on exertion
• Palpitations
• Chest pain
• Presyncope and syncope
• Symptoms of heart failure: dyspnea at rest, orthopnea, paroxysmal nocturnal dyspnea, lower limb swelling, and abdominal distension (ascites).

Systemic involvement can manifest with:

• Gastrointestinal symptoms: dyspepsia, nausea, constipation, early satiety.
• Tongue enlargement (macroglossia)
• Bilateral periorbital discoloration (raccoon eyes)
• Neuropathy symptoms: carpal tunnel syndrome, erectile dysfunction.

Physical examination findings may include:

• Periorbital purpura
• Pedal edema
• Elevated jugular venous pressure (JVP)
• Ascites
• Fine crackles in the lungs
• Macroglossia
• Neuropathy
• Orthostatic hypotension
• Hepatomegaly
• Gastrointestinal bleeding.

Periorbital purpura and macroglossia are considered highly suggestive of cardiac amyloidosis.

Diagnostic Evaluation for Amyloid Heart Disease

Amyloid heart disease is often underdiagnosed due to its diverse systemic manifestations and varied symptom presentation. However, specific findings on cardiovascular investigations can point towards the diagnosis.

Electrocardiogram (ECG) in Amyloid Heart Disease Diagnosis

The 12-lead ECG may show patterns mimicking myocardial infarction (pseudo-infarction pattern), including low voltage in limb leads and Q waves, particularly in anterior and inferior leads (Figure 1). First-degree atrioventricular (AV) block and other AV conduction abnormalities can also be present, more commonly in AL amyloidosis. TTR amyloidosis patients are more likely to exhibit left bundle branch block (LBBB), advanced AV block, and often have non-specific ST-T segment changes with normal limb-lead voltages. Atrial fibrillation is a frequent finding in cardiac amyloidosis patients.

Figure 1: 12-lead electrocardiogram demonstrating low voltage complexes in limb leads and Q waves in anterior leads, indicative of cardiac amyloidosis.

Echocardiography in Amyloid Heart Disease Diagnosis

Echocardiography is often the initial and crucial step in screening and diagnosing cardiac amyloidosis. Characteristic echocardiographic findings include increased myocardial wall thickness and a “sparkling” appearance of the myocardium (Figure 2). Bi-atrial enlargement is typically present. The left ventricle (LV) is usually non-dilated, and LV systolic function is preserved until later stages of the disease. Diastolic dysfunction is almost always present and often progresses rapidly. Pericardial and pleural effusions may also be observed.

Global longitudinal strain (GLS) analysis reveals reduced longitudinal strain in the basal and mid segments of the LV, with relative preservation of apical strain, creating a “cherry on top” pattern, highly suggestive of cardiac amyloidosis (Figure 3). An apical to basal-mid strain ratio greater than 1.1 shows high sensitivity and specificity for the condition.

Clinical features like syncope, angina, or heart failure in conjunction with LV hypertrophy, a bright myocardium on echocardiography, voltage-LVH discordance on ECG, and apical sparing on strain imaging strongly suggest cardiac amyloidosis. Echocardiographic differences exist between TTR and AL amyloidosis. LV hypertrophy tends to be symmetrical in AL but asymmetrical (sigmoid septum appearance) in TTR. TTR amyloidosis often leads to more pronounced systolic and diastolic dysfunction and greater increases in LV and RV mass compared to AL amyloidosis.

Figure 2: Parasternal long-axis view echocardiogram showing thickened and bright myocardium, a key diagnostic clue for cardiac amyloidosis.

Figure 3: Global longitudinal strain bull’s eye map demonstrating the “cherry on top” pattern with reduced basal-mid strain and apical sparing, pathognomonic for cardiac amyloidosis.

Cardiac Magnetic Resonance Imaging (CMR) in Amyloid Heart Disease Diagnosis

CMR has become a vital tool in diagnosing cardiac amyloidosis, helping to differentiate it from conditions like hypertensive heart disease and sarcoidosis, and is valuable for early detection and tissue characterization. However, CMR alone cannot distinguish between TTR and AL amyloidosis. CMR findings characteristic of cardiac amyloidosis include restrictive ventricular morphology, diastolic dysfunction, disproportionate bi-atrial enlargement, and increased myocardial mass and thickness.

Late gadolinium enhancement (LGE) imaging typically shows diffuse circumferential subendocardial LGE, not confined to specific coronary artery territories, and reduced systolic thickening in LGE segments. In advanced cases, LGE may become transmural. Amyloid deposition increases T1 relaxation time and extracellular volume fraction. CMR in amyloidosis typically shows no myocardial edema and rapid gadolinium washout from the LV blood pool. A key feature is the difficulty in nulling normal myocardium on T1 mapping; the myocardium nulls before the LV blood pool, reversing the usual sequence.

Nuclear SPECT in Amyloid Heart Disease Diagnosis

Bone tracer cardiac scintigraphy, particularly using technetium pyrophosphate (^99mTc-PYP), plays a significant role in diagnosing ATTR amyloidosis. Strong cardiac uptake of the bone tracer (visually greater than bone uptake, stage two or three, or heart-to-contralateral chest ratio >1.5 at one hour), combined with echocardiographic features suggestive of cardiac amyloidosis and absence of multiple myeloma signs, is highly indicative of TTR amyloidosis. In contrast, AL amyloidosis typically shows poor or no radioisotope uptake.

Endomyocardial Biopsy in Amyloid Heart Disease Diagnosis

Endomyocardial biopsy remains the gold standard for definitively diagnosing cardiac amyloidosis. Biopsy samples stained with Congo red show characteristic salmon-colored amyloid fibrils, exhibiting “apple-green” birefringence under polarized light. While highly specific, endomyocardial biopsy is invasive and has a sensitivity ranging from 87 to 98%.

Genotyping in Amyloid Heart Disease Diagnosis

Genotyping is crucial in patients diagnosed with ATTR amyloidosis. Over 120 TTR gene variants have been identified as causative. The most common variants include Thr60Ala and Val122Ile. Genotyping is essential for predicting treatment response and prognosis, as variant types and prevalence vary geographically and ethnically.

Treatment and Management Strategies for Amyloid Heart Disease

The treatment of cardiac amyloidosis focuses on addressing the underlying cause and managing heart failure symptoms.

1. Heart Failure Management: Diuretics are fundamental for managing heart failure in AL amyloidosis. Renin-angiotensin-aldosterone system inhibitors (RAAS-I) are often poorly tolerated due to hypotension, particularly in AL amyloidosis, but may be better tolerated in ATTR. Orthostatic hypotension, common due to autonomic dysfunction, can be managed with peripheral vasoconstrictors like midodrine. Beta-blockers are also often poorly tolerated; hypotension upon initiation should raise suspicion for cardiac amyloidosis. Mineralocorticoid receptor antagonists and loop diuretics are vital for heart failure management.
2. AL Amyloidosis Treatment: Treatment mirrors standard multiple myeloma therapy, requiring collaboration between hematologists and cardiologists. The goal is to eliminate paraproteins and stabilize bone marrow. Chemotherapy regimens often include melphalan (alkylating agent) and bortezomib (proteasome inhibitor), sometimes combined with dexamethasone and cyclophosphamide. A positive cardiac response is defined as a ≥30% reduction in B-natriuretic peptides over six months.
3. Heart Transplantation: Orthotopic heart transplantation in AL amyloidosis carries a high risk of recurrence in the transplanted heart. However, in select patients with isolated cardiac involvement, transplantation may be considered if followed by intensive chemotherapy to address the underlying plasma cell dyscrasia. Heart transplantation followed by chemotherapy can achieve a 5-year survival rate of around 60%.
4. ATTR Amyloidosis and Transplantation: Patients with wild-type ATTR amyloidosis and isolated cardiac involvement may be heart transplant candidates, although older age at diagnosis often limits this option. For variant ATTR amyloidosis, liver transplantation is considered to remove the source of mutant TTR protein. Liver transplantation for Val30Met mutation has a 5-year survival rate of approximately 75%. Combined heart and liver transplants may be necessary in cases with autonomic neuropathy to prevent recurrence in the transplanted heart.
5. TTR Stabilizers: For wild-type ATTR amyloidosis, liver transplantation is not indicated. Instead, TTR stabilizer medications like tafamidis are used to slow disease progression.
6. Arrhythmia Management: Rhythm and rate control in atrial arrhythmias are challenging. Beta-blockers are poorly tolerated. Amiodarone is a reasonable antiarrhythmic option. Digoxin can be used for rate control but requires careful titration due to increased risk of toxicity from amyloid binding. Calcium channel blockers are not beneficial and may worsen hypotension. Catheter ablation for atrial flutter may be considered, but atrial fibrillation ablation has high recurrence rates. Anticoagulation is often necessary due to increased thromboembolism risk.
7. Conduction Abnormalities: For atrioventricular block, biventricular pacing is preferred over right ventricular pacing alone due to myocardial stiffness. Implantable cardioverter-defibrillators (ICDs) for primary prevention are generally not indicated but are used for secondary prevention as per standard guidelines.
8. AA Amyloidosis Treatment: Management focuses on treating the underlying chronic inflammatory condition.
9. Isolated Atrial Amyloidosis: Typically requires no specific treatment.

Differential Diagnosis of Amyloid Heart Disease

The differential diagnosis includes other restrictive cardiomyopathies such as cardiac sarcoidosis, glycogen storage diseases, and hemochromatosis, all sharing features like dyspnea, preserved ejection fraction, diastolic dysfunction, and biatrial enlargement. Other conditions mimicking amyloid heart disease on echocardiography, like hypertensive heart disease and hypertrophic cardiomyopathy, must also be considered.

Prognosis in Amyloid Heart Disease

Prognosis varies significantly based on the type of cardiac amyloidosis. Untreated AL amyloidosis has the poorest prognosis, with average survival of 9-24 months. Familial ATTR amyloidosis prognosis is better, with 7-10 year survival, and senile amyloidosis prognosis is 5-7 years. AA amyloidosis prognosis is often longer than ten years, dependent on the underlying inflammatory condition.

ATTR amyloidosis generally has a better prognosis than AL amyloidosis and progresses more slowly, typically presenting later in life. Stem cell transplantation in AL amyloidosis has improved outcomes, with >90% 4-year survival in treated patients, and median survival exceeding 10 years in those with cardiac involvement. However, advanced-stage AL amyloidosis still carries a poor prognosis, with around 50% one-year survival.

Mutant ATTR amyloidosis overall has a 4-year survival of approximately 16%, varying by mutation type. Val30Met mutation has a better prognosis (79% 4-year survival) compared to Val122Ile (40% 4-year survival).

Complications of Amyloid Heart Disease

Complications primarily arise from the structural heart abnormalities caused by amyloid deposition, increasing the risk of:

• Atrial fibrillation: leading to thromboembolism and heart failure.
• Diastolic dysfunction: heart failure, increased mortality, and arrhythmogenesis.
• Heart failure hospitalizations and increased mortality.
• Ventricular arrhythmias and cardiac conduction abnormalities.
• Autonomic neuropathy (in systemic amyloidosis).
• Tendinopathies (in systemic amyloidosis).

Deterrence and Patient Education for Amyloid Heart Disease

Understanding the disease course and treatment options is crucial for patients. Given the systemic nature of amyloidosis, patients need to be aware of potential involvement of multiple organs. Patient education should emphasize the need for a multidisciplinary care team and the differences in heart failure management in amyloidosis compared to other forms of heart failure. Patients need to understand the sensitivity to medications and the necessity for frequent follow-up.

Enhancing Healthcare Team Outcomes in Amyloid Heart Disease

Early diagnosis is key to improving prognosis. A high index of suspicion based on clinical history and investigations is vital for timely diagnosis and treatment initiation. Management necessitates a multidisciplinary team, including cardiologists, hematologists, imaging specialists, and transplant specialists. An individualized approach is crucial for treatment planning. CMR has become an increasingly valuable diagnostic tool, complementing endomyocardial biopsy, the gold standard.

Review Questions

Link to Free Multiple Choice Questions

References

1. Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10-9. [PMC free article: PMC4946260] [PubMed: 27536687]
2. Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]
3. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018 Apr 01;18(Suppl 2):s30-s35. [PMC free article: PMC6334035] [PubMed: 29700090]
4. Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis – A clinical challenge. Int J Cardiol. 2020 Apr 01;304:138-143. [PubMed: 32033783]
5. Lei C, Zhu X, Hsi DH, Wang J, Zuo L, Ta S, Yang Q, Xu L, Zhao X, Wang Y, Sun S, Liu L. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. BMC Cardiovasc Disord. 2021 Jan 21;21(1):43. [PMC free article: PMC7819214] [PubMed: 33478398]
6. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan;28(1):10-21. [PMC free article: PMC5741539] [PubMed: 28739313]
7. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171-4. [PubMed: 26123279]
8. Bajwa F, O’Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev. 2022 Sep;27(5):1471-1484. [PubMed: 34694575]
9. Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail. 2019 Jun;12(6):e005407. [PMC free article: PMC6557425] [PubMed: 31170802]
10. Porcari A, Rossi M, Cappelli F, Canepa M, Musumeci B, Cipriani A, Tini G, Barbati G, Varrà GG, Morelli C, Fumagalli C, Zampieri M, Argirò A, Vianello PF, Sessarego E, Russo D, Sinigiani G, De Michieli L, Di Bella G, Autore C, Perfetto F, Rapezzi C, Sinagra G, Merlo M. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022 Jul;24(7):1227-1236. [PubMed: 35509181]
11. Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013 Mar;18(2):157-62. [PMC free article: PMC6932432] [PubMed: 23530486]
12. Kiotsekoglou A, Saha SK, Nanda NC, Lindqvist P. Echocardiographic diagnosis of cardiac amyloidosis: Does the masquerader require only a “cherry on top”? Echocardiography. 2020 Nov;37(11):1713-1715. [PMC free article: PMC7814664] [PubMed: 33283347]
13. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 04;135(14):1357-1377. [PMC free article: PMC5392416] [PubMed: 28373528]
14. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, Aimo A, Baggiano A, Martinez-Naharro A, Whelan C, Quarta C, Passino C, Castiglione V, Chubuchnyi V, Spini V, Taddei C, Vergaro G, Petrie A, Ruiz-Guerrero L, Moñivas V, Mingo-Santos S, Mirelis JG, Dominguez F, Gonzalez-Lopez E, Perlini S, Pontone G, Gillmore J, Hawkins PN, Garcia-Pavia P, Emdin M, Fontana M. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020 Apr;13(4):909-920. [PubMed: 31864973]
15. Tipoo Sultan FA, Khan MT. Clinical presentation, diagnostic features on cardiac magnetic resonance imaging and outcome of patients with cardiac amyloidosis presenting to a tertiary care setting. J Pak Med Assoc. 2021 Dec;71(12):2802-2805. [PubMed: 35150542]
16. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18;111(2):122-4. [PubMed: 15657385]
17. Li W, Uppal D, Wang YC, Xu X, Kokkinidis DG, Travin MI, Tauras JM. Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021. Diagnostics (Basel). 2021 May 30;11(6) [PMC free article: PMC8228334] [PubMed: 34070853]
18. Bowen K, Shah N, Lewin M. AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report. Case Rep Nephrol. 2012;2012:593460. [PMC free article: PMC3914171] [PubMed: 24555137]
19. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C., THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. [PMC free article: PMC4940135] [PubMed: 27386769]
20. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, Emdin M, Rapezzi C. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022 Dec;24(12):2342-2351. [PMC free article: PMC10084346] [PubMed: 35509173]

Disclosures

Pirbhat Shams declares no relevant financial relationships with ineligible companies.

Intisar Ahmed declares no relevant financial relationships with ineligible companies.